206 related articles for article (PubMed ID: 26976809)
1. Toxic Epidermal Necrolysis in Recessive Dystrophic Epidermolysis Bullosa following Bone Marrow Transplantation.
Boull CL; Hylwa SA; Sajic D; Wagner JE; Tolar J; Hook KP
J Pediatr; 2016 Jun; 173():242-4. PubMed ID: 26976809
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.
Ebens CL; McGrath JA; Tamai K; Hovnanian A; Wagner JE; Riddle MJ; Keene DR; DeFor TE; Tryon R; Chen M; Woodley DT; Hook K; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1238-1246. PubMed ID: 30843184
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
Wagner JE; Ishida-Yamamoto A; McGrath JA; Hordinsky M; Keene DR; Woodley DT; Chen M; Riddle MJ; Osborn MJ; Lund T; Dolan M; Blazar BR; Tolar J
N Engl J Med; 2010 Aug; 363(7):629-39. PubMed ID: 20818854
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous verrucous xanthoma in a bone marrow transplant recipient with recessive dystrophic epidermolysis bullosa.
Boyd AS; Roffwarg D
Pediatr Dermatol; 2013; 30(4):480-3. PubMed ID: 23600757
[TBL] [Abstract][Full Text] [Related]
5. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial.
El-Darouti M; Fawzy M; Amin I; Abdel Hay R; Hegazy R; Gabr H; El Maadawi Z
Dermatol Ther; 2016; 29(2):96-100. PubMed ID: 26439431
[TBL] [Abstract][Full Text] [Related]
6. The Conundrum of Allogeneic Bone Marrow Transplantation for Epidermolysis Bullosa.
Uitto J
J Invest Dermatol; 2018 May; 138(5):1029-1031. PubMed ID: 29258894
[TBL] [Abstract][Full Text] [Related]
7. Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft.
Iinuma S; Aikawa E; Tamai K; Fujita R; Kikuchi Y; Chino T; Kikuta J; McGrath JA; Uitto J; Ishii M; Iizuka H; Kaneda Y
J Immunol; 2015 Feb; 194(4):1996-2003. PubMed ID: 25601922
[TBL] [Abstract][Full Text] [Related]
8. Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa.
Perdoni C; McGrath JA; Tolar J
Stem Cell Res Ther; 2014 Nov; 5(6):121. PubMed ID: 25376815
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa.
Kiuru M; Itoh M; Cairo MS; Christiano AM
Dermatol Clin; 2010 Apr; 28(2):371-82, xii-xiii. PubMed ID: 20447506
[TBL] [Abstract][Full Text] [Related]
10. Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.
Geyer MB; Radhakrishnan K; Giller R; Umegaki N; Harel S; Kiuru M; Morel KD; LeBoeuf N; Kandel J; Bruckner A; Fabricatore S; Chen M; Woodley D; McGrath J; Baxter-Lowe L; Uitto J; Christiano AM; Cairo MS
J Pediatr; 2015 Sep; 167(3):765-9.e1. PubMed ID: 26148662
[TBL] [Abstract][Full Text] [Related]
11. Intradermal Injection of Bone Marrow Mesenchymal Stromal Cells Corrects Recessive Dystrophic Epidermolysis Bullosa in a Xenograft Model.
Ganier C; Titeux M; Gaucher S; Peltzer J; Le Lorc'h M; Lataillade JJ; Ishida-Yamamoto A; Hovnanian A
J Invest Dermatol; 2018 Nov; 138(11):2483-2486. PubMed ID: 29758284
[No Abstract] [Full Text] [Related]
12. Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.
Petrof G; Lwin SM; Martinez-Queipo M; Abdul-Wahab A; Tso S; Mellerio JE; Slaper-Cortenbach I; Boelens JJ; Tolar J; Veys P; Ofuya M; Peacock JL; Martinez AE; McGrath JA
J Invest Dermatol; 2015 Sep; 135(9):2319-2321. PubMed ID: 25905587
[No Abstract] [Full Text] [Related]
13. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases.
Villada G; Roujeau JC; Cordonnier C; Bagot M; Kuentz M; Wechsler J; Vernant JP
J Am Acad Dermatol; 1990 Nov; 23(5 Pt 1):870-5. PubMed ID: 2254472
[TBL] [Abstract][Full Text] [Related]
14. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation.
Takeda H; Mitsuhashi Y; Kondo S; Kato Y; Tajima K
J Dermatol; 1997 Oct; 24(10):635-41. PubMed ID: 9375462
[TBL] [Abstract][Full Text] [Related]
15. Toxic epidermal necrolysis-like acute graft-versus-host disease in pediatric bone marrow transplant patients: Case series and review of the literature.
Sheu Song J; Huang JT; Fraile Alonso MDC; Antaya RJ; Price HN; Funk T; Francois RA; Shah SD
Pediatr Dermatol; 2022 Nov; 39(6):889-895. PubMed ID: 35730149
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses.
Poizeau F; Gaudin O; Le Cleach L; Duong TA; Hua C; Hotz C; Ingen-Housz-Oro S; Sbidian E; Zehou O; Colin A; de Prost N; Lebrun-Vignes B; Chosidow O; Wolkenstein P; Fardet L
J Invest Dermatol; 2018 Jun; 138(6):1293-1300. PubMed ID: 29369774
[TBL] [Abstract][Full Text] [Related]
17. Epidermolysis bullosa acquisita-like reaction associated with penicillamine therapy for sclerodermatous graft-versus-host disease.
Cetkovská P; Pizinger K; Skálová A
J Am Acad Dermatol; 2003 Dec; 49(6):1157-9. PubMed ID: 14639407
[TBL] [Abstract][Full Text] [Related]
18. Placenta-based therapies for the treatment of epidermolysis bullosa.
Nevala-Plagemann C; Lee C; Tolar J
Cytotherapy; 2015 Jun; 17(6):786-795. PubMed ID: 25795271
[TBL] [Abstract][Full Text] [Related]
19. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.
Vanden Oever M; Twaroski K; Osborn MJ; Wagner JE; Tolar J
Pediatr Res; 2018 Jan; 83(1-2):318-324. PubMed ID: 29593249
[TBL] [Abstract][Full Text] [Related]
20. Stem cell therapies for recessive dystrophic epidermolysis bullosa.
Petrova A; Ilic D; McGrath JA
Br J Dermatol; 2010 Dec; 163(6):1149-56. PubMed ID: 20716209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
